Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GNC, Rite Aid expansion plans

This article was originally published in The Tan Sheet

Executive Summary

GNC and Rite Aid announce Aug. 7 an agreement that will nearly double the number of GNC LiveWell locations within Rite Aid stores nationwide by 2014. Under the contract, the firms expect 1,125 GNC locations to be added to the 1,300 currently operating inside Rite Aid stores; the agreement also provides Rite Aid with an option to extend the contract through 2019 and open 250 more stores during that time period. Rite Aid plans to add "several hundred" GNC store-within-Rite Aid store locations during its fiscal year, ending March 1, 2008...

You may also be interested in...



GNC Names CEO, Wind River Woes: Health And Wellness Industry News

Martindale brings familiarity to GNC helm; and FDA warns Wind River Herbs after no response.

Homeopathic Regulatory Evaluation Stocked With FDA Concerns, Industry Answers

The industry wants FDA to consider that a fraction of poison control reports are for homeopathics compared to other drugs and the agency’s current enforcement authorities maintain compliance in manufacturing and marketing the products. FDA is considering whether to maintain its policy that recognizes an ingredient’s inclusion in the HPUS monograph as pre-market approval.

Homeopathic Regulatory Evaluation Stocked With FDA Concerns, Industry Answers

The industry wants FDA to consider that a fraction of poison control reports are for homeopathics compared to other drugs and the agency’s current enforcement authorities maintain compliance in manufacturing and marketing the products. FDA is considering whether to maintain its policy that recognizes an ingredient’s inclusion in the HPUS monograph as pre-market approval.

Related Content

Topics

UsernamePublicRestriction

Register

PS100798

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel